GENFIT To Receive €26.5M After Italy Approves Pricing And Reimbursement For Ipsen’s Iqirvo®

GENFIT, a biopharma company focused on rare and serious liver diseases, announced that Iqirvo® (elafibranor), developed by its partner Ipsen, has received pricing and reimbursement approval in Italy for the treatment of Primary Biliary Cholangitis (PBC). This approval marks a key achievement, triggering a milestone payment of €26.5 million to GENFIT. 

The payment is part of their Licensing and Collaboration Agreement with Ipsen, which provides for this milestone once Iqirvo® is approved for pricing and reimbursement in three major European countries. GENFIT confirmed that milestone payments from Ipsen are not part of its royalty financing agreement with HCRx. The funds from this milestone will support GENFIT’s continued work on treatments for Acute On-Chronic Liver Failure (ACLF) and other serious liver conditions.